GlassScriptPhysician profile
Gary L Graham
NPI 1992129704
$3,740.43
in general payments reported to CMS, 2019-2025
16 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,277 · 2022: $890 · 2023: $680 · 2024: $509 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $924.41 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $484.93 | 2021-2025 | Rexulti |
| Indivior INC. | $454.88 | 2021-2024 | Perseris, Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $424.29 | 2021-2023 | |
| Abbvie INC. | $397.36 | 2021-2023 | |
| Alkermes, INC. | $288.33 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $205.62 | 2021-2022 | |
| Axsome Therapeutics, INC. | $159.54 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $134.10 | 2021-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $128.77 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.84 | 2021 | |
| Neurocrine Biosciences, INC. | $32.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.88 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.57 | 2021 | |
| Noven Therapeutics, LLC | $13.73 | 2024 | Secuado |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.